

Wegener's Granulomatosis (WG) Report

Date: 25 November 2009

"Copyright 2009 CBDMT SARL. All rights reserved. Any unauthorized use or disclosure is prohibited. The information herein was obtained from various sources; we do not guarantee its accuracy or completeness. This research report is prepared for general circulation and is circulated for general information only. It does not have regard to specific investment objectives, financial situation and the particular needs of any particular person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment and trading strategies discussed or recommended in this report and should understand that the statements regarding future prospects may not be realized. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. Neither the information nor any opinion expressed constitutes an offer to buy or sell any securities or options or futures contracts. CBDMT SARL accepts no responsibility or liability whatsoever for any expense, loss or damages arising out of or in any way connected with the use of all or any part of this report. CBDMT SARL does not have long or short position in any securities or options of this issue(s)."

Table of Content

Presentation - Global Information	2
Diagnosis, treatment and management.....	3
Products.....	7
Glucocorticoids.....	7
Cyclophosphamide	7
Products in development	9
Abatacept (Bristol-Myers Squibb)	14
Azathioprine (Bristol-Myers Squibb)	14
Etanercept (Immunex)	16
Mycophenolate mofetil.....	16

List of Tables

Table 1: Systemic manifestations of Wegener’s Granulomatosis.....	5
Table 2: Cytotoxic medications frequently used in the treatment of Wegener’s granulomatosis: strategies to monitor for and prevent toxicity.....	6
Table 3: Clinical Trial in Recruiting Status for Wegener’s Granulomatosis	9
Table 4: Clinical Trial Completed for Wegener’s Granulomatosis.....	11